Nav: Home

Tighten the grip on metastasis

March 17, 2017

Metastasis is the major cause of cancer-related death and its appearance remains a phenomenon that is difficult to predict and manage. We now know that, prior to the arrival of the cancer cells, tumours prepare the ground in the organ that they will later colonise. These areas with ideal conditions for the onset of metastasis are called pre-metastatic niches and targeting them will help improve patient survival. These questions are the subject of a review paper published in Nature Reviews by an international group of experts in this field, including Héctor Peinado, head of the Microenvironment and Metastasis Group at the Spanish National Cancer Research Centre (CNIO).

There are certain areas and organs in the body where the onset of metastasis is more common. Lungs, bones, brain... What's more, each tumour has a predilection for colonising specific areas. The problem is that we are still unable to anticipate where metastasis occurs and when it does, it is often too late. However, Peinado and his colleagues have known for some years that the areas that are going to be affected by metastasis undergo changes before the arrival of the tumour cells.

These areas are what David Lyden, Weill Cornell Medicine (USA), termed 'pre-metastatic niches' several years ago. In these niches, we can detect changes that will later allow the survival and growth of tumour cells. These changes are caused by soluble factors and extracellular vesicles secreted by the primary tumour. "Emerging evidence from our laboratory and others identified pre-metastatic niches in patients with various cancers. This is a paradigm shift in our understanding of metastasis that will be the cornerstone for developing strategies for the preventive treatment of metastasis, rather than treating metastasis after the fact."

GETTING AHEAD OF METASTASIS

Therefore, the challenge is - and this is the topic of the paper - to be able to identify the niches before metastasis occurs. "The three events that take place and that could serve to detect these niches are vascular leakiness, infiltration of immune cells (local inflammation) and remodelling of the organ," explains Peinado. These three processes facilitate the emergence of metastasis but can also serve as markers of future metastasis. "A better understanding of the biology underlying the inflammation and blood vessel dysfunction in pre-metastatic niches will allow us to identify therapies to block metastatic progression", says Haiying Zhang, the paper's co-author, also from Weill Cornell Medicine.

"The more we move forward in the early detection of metastasis, the higher the survival rates will be," said Peinado. This is, precisely, the crux of the matter, since most cancer patients succumb mainly to metastasis, while the treatment of the primary tumours is quite advanced. "If we can predict that a tumour is going to metastasize and detect where, and we can stop it in that time window, it will be easier to treat cancer," pointed out Peinado.

One of the things this review assesses is the development of molecular imaging techniques that can complement classic tests to analyse and detect the formation of these future metastatic niches. By using markers that indicate the formation of a niche, it would be possible to learn where a tumour is likely to metastasize.

The next step would be to prevent the metastasis. Once again, the study of these niches is providing information on how this can be achieved. Acting on changes in the blood vessels, blocking the signals that primary tumours send, or keeping these niches in a dormant state (as happens for years in some patients) are some of the strategies that are being explored in the laboratory. "Identifying strategies to restore immune function in pre-metastatic niches will also be crucial for the success of therapies aimed at preventing metastasis", added Irina Matei, also a co-author from Weill Cornell Medicine.

"All this could contribute to prevention and therapy, but -Peinado says- although the concept is very interesting and has great potential, much work remains to be done to done to translate from bench to bedside". There are ongoing studies involving various tools and approaches such as the analysis of circulating vesicles (exosomes) in liquid biopsies with promising results to predict metastatic outcome and organotropism in the pre-clinical setting, but we will have to wait for it to reach the clinical phase.
-end-


Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".